Prevalence of XXXX @entity984 pre-treatment resistance associated amino acid variants within a Scottish cohort.

@entity1 @entity71630 @entity71632 @entity3531 @entity984 @entity71634 @entity71629 @entity71633 @entity2263 @entity71631
BACKGROUND: Protease inhibitors (PI) including boceprevir, telaprevir and simeprevir have revolutionised @entity3531 genotype 1 treatment since their introduction. A number of pre-treatment resistance associated amino acid variants (RAVs) and polymorphisms have been associated with reduced response to treatment. OBJECTIVES: We measured the prevalence of RAVs/polymorphisms in a PI treatment-na  ve @entity3531 genotype 1 Scottish cohort using Sanger sequencing. STUDY DESIGN: Chronically infected, treatment-na  ve, @entity3531 genotype 1 @entity1 (n=146) attending NHS Greater Glasgow and Clyde clinics were investigated for RAVs/polymorphisms to the PIs boceprevir, telaprevir and simeprevir. The @entity984 /4A region was amplified by nested polymerase chain reaction. The 1.4kb amplified product was sequenced using an ABI 3710XL DNA sequencer. Sequence analysis was performed using web-based ReCall ( @entity2263 .10). Amino acid positions 36, 41, 43, 54, 55, 80, 109, 122, 155, 156, 168 and 170 were analysed for RAVs/polymorphisms. RESULTS: Overall, 23.29% (34/146) of @entity1 had an RAV or polymorphism detected. Overall, 13.69% (20/146) of @entity1 had @entity3531 virus that contained the Q8 K polymorphism. Other RAVs detected were: @entity71629 0.70% (1/146), @entity71630 0.70% (1/146), @entity71631 6.85% (10/146), @entity71632 3.42% (5/146) and V/ @entity71633 0.68% (1/146). Four @entity1 had dual combinations of mutations ( @entity71631 + @entity71630 ; @entity71631 + @entity71632 and 2 @entity1 with @entity71631 + @entity71634 ). CONCLUSIONS: @entity71634 was the most prevalent baseline polymorphism detected in the Scottish cohort. Simeprevir treatment is not recommended in @entity1 infected with the @entity71634 genotype 1a variant. This highlights the need for baseline sequencing prior to administration of this drug in this population.
